Browse the evidence

Weight loss achieved through GLP-1–based antiobesity medications affects weight regain, fat-free mass, and skeletal muscle mass in people with obesity.

Practitioners should consider the impact of GLP-1 medications on body composition when managing obesity.

Wegovy rose from 989 in 2021 to 2992 in 2022.

The increase in Wegovy usage suggests a rising interest in GLP-1 receptor agonists for weight loss.

The monthly growth rates were 83.9% for Ozempic and 119.2% for Wegovy.

High monthly growth rates indicate a significant trend towards the use of GLP-1 receptor agonists for weight loss.

Liraglutide, 3.0 mg, is safe with no serious adverse events or treatment-related deaths reported.

Liraglutide can be considered a safe option for weight management in the studied population.

Resistance training (RT) induces significant endogenous hormonal elevations.

Incorporating resistance training can enhance hormonal levels beneficial for muscle growth.

Bariatric surgery and GLP-1 receptor agonists have similar effects on glycemic control.

Both treatment options can be considered for glycemic control in obese patients.

Tirzepatide treatment was associated with lower hazards of all-cause mortality compared to GLP-1 RA (adjusted hazard ratio [AHR], 0.58; 95% CI, 0.45-0.75).

Practitioners may consider tirzepatide as a safer option for reducing mortality risk in patients with type 2 diabetes.

Tirzepatide treatment was associated with lower hazards of major adverse cardiovascular events (MACEs) compared to GLP-1 RA (AHR, 0.80; 95% CI, 0.71-0.91).

Tirzepatide may be a preferable treatment option for reducing cardiovascular risks in patients with type 2 diabetes.

Twins on the vegan diet had a significant mean decrease in fasting insulin level of -2.9 μIU/mL after 8 weeks.

Clinicians may consider a vegan diet to improve insulin sensitivity in patients.

There is a causal relationship between glucose-stimulated insulin secretion and body weight.

Practitioners should consider the role of insulin secretion in weight management strategies.

A significant improvement was observed in eating behavior in the probiotic group compared to the placebo group.

Probiotic supplementation may help improve eating behaviors in this population.

Serum levels of oxytocin increased and NPY decreased significantly in the probiotic group compared to the placebo group.

Probiotics may positively influence appetite-regulating hormones in obese women with food addiction.

Betaine and choline concentrations were associated with greater insulin sensitivity.

Increased intake of betaine and choline may enhance insulin sensitivity, suggesting potential dietary recommendations.

Targeting amylin receptors improves weight control and may act additively with other treatments.

Combining treatments targeting amylin receptors may enhance obesity management strategies.

GLP-1 receptor agonists (semaglutide, liraglutide) significantly improve cardiovascular biomarkers—including hs-CRP, systolic blood pressure, and lipid profiles—independent of glycemic control.

GLP-1 medications like semaglutide do more than just help you lose weight; they directly improve your heart health markers. They significantly lower systemic inflammation (hs-CRP), improve blood vessel function, lower blood pressure, and improve lipid profiles. These benefits happen even if you don't have diabetes, proving the drug protects your blood vessels directly. You should be aware of the slightly increased risk of gallbladder issues due to rapid weight loss, so your doctor will monitor your baseline risk.

Menopause is associated with a substantial decrease in endogenous oestrogen concentrations and alterations in body weight, adipose tissue distribution, and energy expenditure, which can predispose women to the development of type 2 diabetes mellitus (T2DM).

Practitioners should be aware of the increased risk of T2DM in menopausal women due to hormonal changes.

Hormone Replacement Treatment (HRT) has a favourable effect on glucose homeostasis in women with T2DM.

HRT may be considered for managing glucose levels in menopausal women with T2DM.

Liquid meal replacements lead to modest reductions in systolic blood pressure of −4.97 mmHg (−7.32 to −2.62).

Using liquid meal replacements may contribute to lowering blood pressure in this population.

GLP1-RA treatment is associated with improvements in mental health-related quality of life compared with placebo (g = 0.15; P < .001).

GLP1-RAs may enhance mental health quality of life in this population.

There are quantitative sex differences in the response to GLP-1 and its analogs.

Practitioners should consider sex differences when prescribing GLP-1 analogs.

Alterations in metabolism, hormonal status, explosive strength, and psychological aspects of eating were observed during precontest preparation; however, all of these variables recovered quickly postcompetition.

Practitioners should note that while metabolic and hormonal changes occur during preparation, they are reversible postcompetition.

The share of prescriptions for semaglutide (Wegovy) increased to 27.7% among advanced practice practitioners (APPs) by February 2024.

Practitioners should consider the growing preference for semaglutide in obesity treatment.

The odds of discontinuation of glucose-lowering medications at year 1 differed by bMVPA timing, with the afternoon group having the highest odds (odds ratio 2.13).

Understanding the timing of physical activity may help in managing medication strategies for diabetes patients.

Tirzepatide resulted in significant decreases in systolic blood pressure of median -4.20 mmHg for 5 mg, -5.34 mmHg for 10 mg, and -5.77 mmHg for 15 mg.

Tirzepatide may be an effective treatment for reducing systolic blood pressure in patients.